Voyeurs were well-paying hole-lookers in especially Parisian brothels, a commercial innovation described as far back as 1857 but not gaining much notoriety until the 1880s, and not attracting formal medical-forensic recognition until the early 1890s. Society has accepted the use of the term voyeur as a description of anyone who views the intimate lives of others, even outside of a sexual context. This term is specifically used regarding reality television and other media which allow people to view the personal lives of others. This is a reversal from the historical perspective, moving from a term which describes a specific population in detail, to one which describes the general population vaguely. One of the few historical theories on the causes of voyeurism comes from psychoanalytic theory. Psychoanalytic theory proposes that voyeurism results from a failure to accept castration anxiety and as a result of failure to identify with the father. Prevalence
Voyeurism has high prevalence rates in most studied populations. Voyeurism was initially believed to only be present in a small portion of the population. This perception changed when Alfred Kinsey discovered that 30% of men prefer coitus with the lights on. This behaviour is not considered voyeurism by todays diagnostic standards, but there was little differentiation between normal and pathological behaviour at the time. Subsequent research showed that 65% of men had engaged in peeping, which suggests that this behaviour is widely spread throughout the population. Congruent with this, research found voyeurism to be the most common sexual law-breaking behaviour in both clinical and general populations.
This proposal is based on an initial literature review on the safety of low dose CBD published by the TGA in April 2020. Epidyolex was approved, for the adjunctive therapy of seizures associated with Lennox-Gastaut syndrome or with Dravet syndrome, on 18 September 2020, and added to the ARTG on 21 September 2020. Bulgaria
In 2020, Bulgaria became the first country in the European Union to allow retail sales of food products and supplements containing CBD, despite the ongoing discussion within the EU about the classification of CBD as a novel food. But there exists a legal gap because of the lack of a legally-permissible minimum amount of THC in the products containing cannabinoids. Canada
In October 2018, cannabidiol became legal for recreational and medical use by the federal Cannabis Act. As of August 2019, CBD products in Canada could only be sold by authorized retailers or federally licensed medical companies, limiting their access to the general public. Nonetheless, with online delivery services and over 2,600 authorized cannabis retail stores as of October 2021, accessibility has steadily increased over time. The Canadian government states that CBD products "are subject to all of the rules and requirements that apply to cannabis under the Cannabis Act and its regulations." It requires "a processing licence to manufacture products containing CBD for sale, no matter what the source of the CBD is, and that CBD and products containing CBD, such as cannabis oil, may only be sold by an authorized retailer or licensed seller of medical CBD."